J Mater Sci Mater Med:基于聚ε-赖氨酸的水凝胶基质可用于移植角膜内皮细胞的扩增

2020-04-22 MedSci原创 MedSci原创

角膜内皮细胞逐渐丧失导致的角膜内皮功能障碍(CE)导致角膜水肿和严重的视力损害。目前的治疗方法是依靠供体异体组织来替代受损的CE。供体角膜的短缺要求开发生物材料,使角膜内皮细胞(CECs)在体外扩张。

角膜内皮细胞逐渐丧失导致的角膜内皮功能障碍(CE)导致角膜水肿和严重的视力损害。目前的治疗方法是依靠供体异体组织来替代受损的CE。供体角膜的短缺要求开发生物材料,使角膜内皮细胞(CECs)在体外扩张。本研究调查了使用聚ε-赖氨酸(pεK)与辛二酸交联的合成肽水凝胶作为CECs扩增和CE移植物的潜在底物。

 

结果显示,PεK水凝胶的性能得到了优化,从而产生了一种薄、透明、多孔和坚固的基质。人角膜内皮细胞系(HCEC-12)在pεK水凝胶上附着并生长7天后,在pεK水凝胶上生长,而原生猪CECs(pCECs)从pεK水凝胶上脱落。胶原蛋白I、胶原蛋白IV和纤维蛋白的预吸附到pεK水凝胶上增加了pCEC在24 h时的粘附性,7天后形成汇流单层。预先吸附的层压蛋白、硫酸软骨素或商业化的FNC涂层混合物(纤维蛋白、胶原蛋白和白蛋白)观察到的细胞粘附力最小。使用合成的细胞结合肽H-Gly-Gly-Grg-Gly-Arg-Gly-Asp-Gly-Gla-OH(RGD)或α2β1整合蛋白识别序列H-Asp-Gly-Glu-Ala-OH(DGEA)对pεK水凝胶进行功能化处理,仅用RGD肽就能增强pCEC的粘附性。

 

综上所述,这些结果表明,pεK水凝胶可以通过共价结合RGD的共价结合来提供CEC附着和生长的表面。因此,提供了一种具有治疗性应用的合成基质,可用于异源性CEC的扩增和替换受损的CE。

 

原始出处:

 

Stephnie KennedyRebecca Lace, et al., Poly-ε-lysine based hydrogels as synthetic substrates for the expansion of corneal endothelial cells for transplantation. J Mater Sci Mater Med. 2019; 30(9): 102.Published online 2019 Sep 4. doi: 10.1007/s10856-019-6303-1

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757204, encodeId=06341e572044a, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 21 00:15:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308076, encodeId=a7fa13080e697, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349183, encodeId=07d01349183b7, content=<a href='/topic/show?id=4337909284a' target=_blank style='color:#2F92EE;'>#角膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90928, encryptionId=4337909284a, topicName=角膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461057, encodeId=833b146105e93, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592172, encodeId=c73f15921e2b3, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610445, encodeId=4bfc1610445a1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1757204, encodeId=06341e572044a, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 21 00:15:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308076, encodeId=a7fa13080e697, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349183, encodeId=07d01349183b7, content=<a href='/topic/show?id=4337909284a' target=_blank style='color:#2F92EE;'>#角膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90928, encryptionId=4337909284a, topicName=角膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461057, encodeId=833b146105e93, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592172, encodeId=c73f15921e2b3, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610445, encodeId=4bfc1610445a1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=)]
    2020-04-24 tastas
  3. [GetPortalCommentsPageByObjectIdResponse(id=1757204, encodeId=06341e572044a, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 21 00:15:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308076, encodeId=a7fa13080e697, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349183, encodeId=07d01349183b7, content=<a href='/topic/show?id=4337909284a' target=_blank style='color:#2F92EE;'>#角膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90928, encryptionId=4337909284a, topicName=角膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461057, encodeId=833b146105e93, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592172, encodeId=c73f15921e2b3, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610445, encodeId=4bfc1610445a1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=)]
    2020-04-24 snowpeakxu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1757204, encodeId=06341e572044a, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 21 00:15:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308076, encodeId=a7fa13080e697, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349183, encodeId=07d01349183b7, content=<a href='/topic/show?id=4337909284a' target=_blank style='color:#2F92EE;'>#角膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90928, encryptionId=4337909284a, topicName=角膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461057, encodeId=833b146105e93, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592172, encodeId=c73f15921e2b3, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610445, encodeId=4bfc1610445a1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=)]
    2020-04-24 lishizhe
  5. [GetPortalCommentsPageByObjectIdResponse(id=1757204, encodeId=06341e572044a, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 21 00:15:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308076, encodeId=a7fa13080e697, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349183, encodeId=07d01349183b7, content=<a href='/topic/show?id=4337909284a' target=_blank style='color:#2F92EE;'>#角膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90928, encryptionId=4337909284a, topicName=角膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461057, encodeId=833b146105e93, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592172, encodeId=c73f15921e2b3, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610445, encodeId=4bfc1610445a1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1757204, encodeId=06341e572044a, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Tue Jul 21 00:15:50 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308076, encodeId=a7fa13080e697, content=<a href='/topic/show?id=edd364149bc' target=_blank style='color:#2F92EE;'>#水凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64149, encryptionId=edd364149bc, topicName=水凝胶)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349183, encodeId=07d01349183b7, content=<a href='/topic/show?id=4337909284a' target=_blank style='color:#2F92EE;'>#角膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90928, encryptionId=4337909284a, topicName=角膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=568152, createdName=snowpeakxu, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461057, encodeId=833b146105e93, content=<a href='/topic/show?id=de4331310a4' target=_blank style='color:#2F92EE;'>#凝胶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31310, encryptionId=de4331310a4, topicName=凝胶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09e6383467, createdName=lishizhe, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592172, encodeId=c73f15921e2b3, content=<a href='/topic/show?id=cce892599c3' target=_blank style='color:#2F92EE;'>#赖氨酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92599, encryptionId=cce892599c3, topicName=赖氨酸)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c5e18091046, createdName=w363522455, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610445, encodeId=4bfc1610445a1, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 24 06:15:50 CST 2020, time=2020-04-24, status=1, ipAttribution=)]
    2020-04-24 智慧医人

相关资讯

Int J Biol Macromol:新型生物活性丝素蛋白/透明质酸水凝胶的制备及应用

蛋白质和多糖是哺乳动物软组织的主要成分。本研究中,研究人员制备了一种快速水凝胶,通过丝素蛋白(SF)和透明质酸(HA)混合水凝胶模拟天然细胞外基质。 SF/HA水凝胶制备有效,形成时间短。随着HA含量的增加,水凝胶的吸水率、孔隙率和断裂强度增加,而接触角减小显示水凝胶的亲水性极大地提高。特别是,比例为5:5的SF/HA水凝胶具有最高的吸水率和机械性能。复合水凝胶的分子构象主要为无定形结构,并且随着

英国NHS倡导,使用水凝胶降低放射治疗前列腺癌患者的副作用

前列腺癌是男性中最常见的癌症,每年在英格兰新诊断出的病例超过40000例。当足够早地发现前列腺癌时,放射治疗是一种非常有效的治疗方法,高能X射线靶向前列腺,杀死癌细胞并阻止扩散。然而附近的健康器官也会受到影响。SpaceOAR水凝胶充当间隔物,通过临时将其远离治疗中使用的高剂量辐射,减少治疗期间损伤直肠的辐射量。水凝胶作为NHS特定创新计划的一部分得到资助,该计划在过去三年中已经使超过300000

超声辅助冲洗枪取出乳房内聚丙烯酰胺水凝胶临床应用

聚丙烯酰胺水凝胶(polyacrylamide hydmgel, PAHG)是一种无色透明胶冻状的液态化学合成物, 作为软组织填充材料,曾广泛应用于整形外科领 域[1]。经过远期临床应用后发现,该物质容易导致乳 房感染、变形、结节、囊肿、局部疼痛等并发症和后 遗症。因此,整形外科医师们一直致力于探索如何 彻底地取出乳房组织内的 PAHG。自 2017 年 6 月至 2019 年 6 月,中国医科大

Sci Tran Med:轻轻一涂病痛走掉,新型水凝胶预防治疗伤口感染两不误

瑞典隆德大学的研究人员基于人体的天然肽防御系统开发了一种新型水凝胶。它可以预防和治疗伤口感染,杀死多重耐药菌。

JACC:FDA I期临床试验显示,用于修复心脏的水凝胶可安全注射到人体内

最近的一项研究评估了心肌细胞外基质水凝胶,VentriGel,经心内膜注射,治疗左心室(LV)功能障碍的早期和晚期心肌梗死(MI)患者的安全性和可行性。

聚丙烯酰胺水凝胶隆乳术后 16 年 乳房罕见畸形一例报告

患者女性,42 岁, 16 年前于某整形美容医院行“双侧乳 房 PAHG 注射隆乳术”,双侧乳房注射量共 350 ml;手术顺 利,术后无明显并发症, 自觉乳房外形满意。6 年前无诱因下 发现双侧乳房增大变形,未做任何处理。